{"id":555800,"date":"2025-04-28T06:55:38","date_gmt":"2025-04-28T03:55:38","guid":{"rendered":"https:\/\/analyse.optim.biz\/?p=555800"},"modified":"2025-04-28T06:55:38","modified_gmt":"2025-04-28T03:55:38","slug":"marile-companii-farmaceutice-incep-sa-se-mute-in-sua-pentru-a-evita-tarifele-vamale","status":"publish","type":"post","link":"https:\/\/analyse.optim.biz\/?p=555800","title":{"rendered":"Marile companii farmaceutice \u00eencep s\u0103 se mute \u00een SUA pentru a evita tarifele vamale"},"content":{"rendered":"<div class=\"post-content\">\n<p class=\"p1\"><span class=\"s1\">Marile grupuri farmaceutice au \u00eenceput s\u0103 \u00ee\u0219i relocalizeze produc\u021bia \u00een Statele Unite, cea mai mare pia\u021b\u0103 de medicamente din lume. Timp de 30 de ani, produsele farmaceutice au fost scutite de taxe vamale, \u00eens\u0103 o eventual\u0103 contestare a acestui privilegiu de c\u0103tre Washington a determinat o sc\u0103dere a cota\u021biilor bursiere \u00een acest sector \u0219i a determinat reac\u021bia greilor din industria farmaceutic\u0103, potrivit <a href=\"https:\/\/www.bfmtv.com\/economie\/entreprises\/capitulation-ou-pretexte-le-big-pharma-amorce-des-relocalisations-aux-etats-unis-pour-eviter-les-droits-de-douane_AD-202504260249.html\" target=\"_blank\" rel=\"noopener\">BFM TV<\/a>.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Prin urmare, de la \u00eenceputul r\u0103zboiului comercial din aceast\u0103 iarn\u0103, unele mari companii farmaceutice au luat ini\u021biativa, anun\u021b\u00e2nd cu mare fast c\u0103 investesc pentru a-\u0219i spori produc\u021bia \u00een Statele Unite.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Companiile americane Eli Lilly (27 de miliarde de dolari), Johnson &amp; Johnson (55 de miliarde de dolari \u00een urm\u0103torii patru ani) \u0219i Merck, cu inaugurarea unei fabrici de vaccinuri \u00een Carolina de Nord, au fost primele care au anun\u021bat investi\u021bii.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Concuren\u021bii europeni au urmat exemplul \u00een aprilie: elve\u021bianul Novartis a anun\u021bat c\u0103 inten\u021bioneaz\u0103 s\u0103 investeasc\u0103 23 de miliarde de dolari \u00een Statele Unite \u00een cinci ani, iar compatriotul s\u0103u Roche 50 de miliarde de dolari (43 de miliarde de euro).<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u201eSe poate pune problema unui exerci\u021biu de comunicare \u00een acest moment\u201d, observ\u0103 Nicolas Picard, un manager de fonduri specializat \u00een s\u0103n\u0103tate la CPRAM.<\/span><\/p>\n<h3 class=\"p1\"><span class=\"s1\">Anticiparea cererilor SUA<\/span><\/h3>\n<p class=\"p1\"><span class=\"s1\">\u201eCeea ce este special la anun\u021burile companiilor este c\u0103 le comunic\u0103 at\u00e2t de \u201eputernic\u201d \u2013 ceea ce nu f\u0103ceau \u00een trecut\u201d, remarc\u0103 Stefan Schneider, analist la Vontobel, care acoper\u0103 Roche \u0219i Novartis.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u00cen opinia sa, acest lucru se \u00eent\u00e2mpl\u0103 pentru a oferi guvernului american \u201er\u0103spunsurile pe care le a\u0219teapt\u0103 la cererile sale\u201d, \u00een contextul \u00een care Washingtonul \u00eencearc\u0103 s\u0103 repatrieze fabrici \u00een SUA \u0219i s\u0103 creeze astfel locuri de munc\u0103.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Dar, la fel ca al\u021bi exper\u021bi intervieva\u021bi de AFP, Stefan Schneider consider\u0103, de asemenea, c\u0103 \u201eplanurile globale de investi\u021bii \u00een Statele Unite existau deja \u00eenainte de venirea la putere a noului guvern\u201d.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Stimulente pentru a produce \u00een Statele Unite au fost elaborate sub administra\u021bia Biden.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Grupul francez Sanofi nu a anun\u021bat nicio nou\u0103 investi\u021bie \u00een SUA, dar a indicat joi c\u0103 ar putea \u201epoten\u021bial\u201d s\u0103 fac\u0103 acest lucru \u00een viitor, \u00een func\u021bie de necesit\u0103\u021bi. Sanofi a subliniat c\u0103 a planificat s\u0103 produc\u0103 mai mult \u00een Statele Unite cu mult \u00eenainte de sosirea noii administra\u021bii Trump. Ca mul\u021bi dintre concuren\u021bii s\u0103i, grupul Tricolor genereaz\u0103 aproximativ jum\u0103tate din v\u00e2nz\u0103rile sale \u00een Statele Unite, unde se afl\u0103 doar 25% din produc\u021bia sa, repartizat\u0103 \u00een cinci fabrici.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">A investi mai mult nu \u00eenseamn\u0103 neap\u0103rat deschiderea de noi loca\u021bii, dar ar putea \u00eensemna cre\u0219terea capacit\u0103\u021bii de produc\u021bie a fabricilor existente sau utilizarea mai intens\u0103 a subcontractan\u021bilor locali.<\/span><\/p>\n<h3 class=\"p1\"><span class=\"s1\">Accentul pe pre\u021b<\/span><\/h3>\n<p class=\"p1\"><span class=\"s1\">Potrivit lui Stefan Schneider, ratele de utilizare a diferitelor uzine de produc\u021bie \u201ear putea fi acum mai ridicate pentru siturile americane dec\u00e2t se preconiza ini\u021bial\u201d, iar produc\u0103torii ar putea \u00eencerca acum \u201es\u0103 produc\u0103 produse pentru pia\u021ba american\u0103 \u00een Statele Unite\u201d.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u201eProblema pre\u021bului medicamentelor se adaug\u0103 la problema locului unde sunt produse\u201d, subliniaz\u0103 Nicolas Picard, preciz\u00e2nd c\u0103 Statele Unite sunt \u201cprima pia\u021b\u0103 \u00een termeni de valoare pentru toate companiile farmaceutice\u201d.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Este deosebit de interesant s\u0103 vinzi produse farmaceutice acolo, deoarece pre\u021bul unui medicament este semnificativ mai mare dec\u00e2t \u00een Europa, din cauza unui sistem de s\u0103n\u0103tate \u00een care asigur\u0103torii priva\u021bi joac\u0103 un rol major.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">Cu toate acestea, actorii din industrie subliniaz\u0103 c\u0103 pre\u021burile medicamentelor brevetate sunt stabilite de guverne sau prin acorduri pe termen lung. \u00cen opinia lor, acest lucru \u00eenseamn\u0103 c\u0103, spre deosebire de industria bunurilor de lux, de exemplu, ace\u0219tia nu vor putea transfera cre\u0219terile rezultate din taxele vamale asupra pre\u021burilor lor de v\u00e2nzare. Prin urmare, marjele lor ar putea suferi, chiar dac\u0103 r\u0103m\u00e2n foarte ridicate.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u00cen acela\u0219i timp, laboratoarele europene fac presiuni pentru a se lua m\u0103suri de cre\u0219tere a competitivit\u0103\u021bii sectorului pe B\u0103tr\u00e2nul Continent, inclusiv o revizuire \u00een cre\u0219tere a pre\u021burilor.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\">\u00cen plus fa\u021b\u0103 de taxele vamale, sectorul este preocupat de riscul \u00eent\u00e2rzierilor \u00een ceea ce prive\u0219te autoriza\u021biile de introducere pe pia\u021b\u0103 a noilor produse.<\/span><\/p>\n<div id=\"vi-wrap\">\n<h4>Urm\u0103re\u0219te mai jos produc\u021biile video ale G4Media:<\/h4>\n<\/div>\n<\/div>\n<p> Source URL: https:\/\/www.g4media.ro\/marile-companii-farmaceutice-incep-sa-se-mute-in-sua-pentru-a-evita-tarifele-vamale.html<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marile grupuri farmaceutice au \u00eenceput s\u0103 \u00ee\u0219i relocalizeze produc\u021bia \u00een Statele Unite, cea mai mare pia\u021b\u0103 de medicamente din lume. Timp de 30 de ani, produsele farmaceutice au fost scutite de taxe vamale, \u00eens\u0103 o eventual\u0103 contestare a acestui privilegiu de c\u0103tre Washington a determinat o sc\u0103dere a cota\u021biilor bursiere \u00een acest sector \u0219i a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":555801,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24],"class_list":["post-555800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politics","tag-g4media"],"_links":{"self":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/555800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=555800"}],"version-history":[{"count":0,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/555800\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/media\/555801"}],"wp:attachment":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=555800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=555800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=555800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}